@article{21274, keywords = {Female, Humans, Aged, Male, Middle Aged, Risk Factors, Prognosis, Predictive Value of Tests, Incidence, Risk Assessment, Time Factors, Biological Markers/blood, Cardiovascular Diseases/ blood/diagnosis/epidemiology, Cystatin C/blood, Intramolecular Oxidoreductases/blood, Lipocalins/blood, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Renal Insufficiency, Chronic/ blood/diagnosis/epidemiology, Troponin T/blood, United States/epidemiology, beta 2-Microglobulin/blood}, author = {Matsushita K. and Ballew S. and Ballantyne C. and Woodward Mark and Sang Y. and Astor B. and Solomon S. and Coresh J. and Hoogeveen R.}, title = {Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study}, abstract = {

OBJECTIVE: Traditional predictors suboptimally predict cardiovascular disease (CVD) in individuals with chronic kidney disease (CKD). This study compared 5 nontraditional cardiac and kidney markers on the improvement of cardiovascular prediction among those with CKD. APPROACH AND RESULTS: Among 8622 participants aged 52 to 75 years in the Atherosclerosis Risk in Communities (ARIC) Study, cardiac troponin T, N-terminal pro-B-type natriuretic peptide, cystatin C, beta2-microglobulin, and beta-trace protein were compared for improvement in predicting incident CVD after stratifying by CKD status (940 participants with CKD [kidney dysfunction or albuminuria]). During a median follow-up of 11.9 years, there were 1672 CVD events including coronary disease, stroke, and heart failure (336 cases in CKD). Every marker was independently associated with incident CVD in participants with and without CKD. The adjusted hazard ratios (per 1 SD) were larger for cardiac markers than for kidney markers, particularly in CKD (1.61 [95% confidence interval, 1.43-1.81] for cardiac troponin T, 1.50 [1.34-1.68] for N-terminal pro-B-type natriuretic peptide, and <1.26 for kidney markers). Particularly in CKD group, cardiac markers compared with kidney markers contributed to greater c-statistic increment (0.032-0.036 versus 0.012-0.015 from 0.679 with only conventional predictors in CKD and 0.008-0.011 versus 0.002-0.010 from 0.697 in non-CKD) and categorical net reclassification improvement (0.086-0.127 versus 0.020-0.066 in CKD and 0.057-0.077 versus 0.014-0.048 in non-CKD). The superiority of cardiac markers was largely consistent in individual CVD outcomes. CONCLUSIONS: A greater improvement in cardiovascular prediction was observed for cardiac markers than for kidney markers in people with CKD. These results suggest that cardiac troponin T and N-terminal pro-B-type natriuretic peptide are useful for better CVD risk classification in this population.

}, year = {2014}, journal = {Arteriosclerosis, Thrombosis, and Vascular Biology}, volume = {34}, edition = {2014/05/31}, number = {8}, pages = {1770-7}, isbn = {1524-4636 (Electronic)
1079-5642 (Linking)}, note = {Matsushita, Kunihiro
Sang, Yingying
Ballew, Shoshana H
Astor, Brad C
Hoogeveen, Ron C
Solomon, Scott D
Ballantyne, Christie M
Woodward, Mark
Coresh, Josef
HHSN268201100005C/PHS HHS/United States
HHSN268201100006C/PHS HHS/United States
HHSN268201100007C, HHSN268201100008C/PHS HHS/United States
HHSN268201100009C/HL/NHLBI NIH HHS/United States
HHSN268201100009C, HHSN268201100010C/PHS HHS/United States
HHSN268201100011C/PHS HHS/United States
HHSN268201100012C/PHS HHS/United States
R01 DK089174/DK/NIDDK NIH HHS/United States
R01DK076770/DK/NIDDK NIH HHS/United States
Comparative Study
Multicenter Study
Research Support, N.I.H., Extramural
United States
Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1770-7. doi: 10.1161/ATVBAHA.114.303465. Epub 2014 May 29.}, language = {eng}, }